Stockreport

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies [Yahoo!...

Compugen Ltd. - Ordinary Shares  (CGEN) 
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: cgen.com/investors/overview
PDF with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitor [Read more]